Please use this identifier to cite or link to this item:
Title: Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
Authors: Davies, MJ
Donnelly, R
Barnett, AH
Jones, S
Nicolay, C
Kilcoyne, A
First Published: Dec-2009
Citation: DIABETES OBES METAB, 2009, 11 (12), pp. 1153-1162
Abstract: The Helping Evaluate Exenatide in overweight patients with diabetes compared with Long-Acting insulin (HEELA) study was designed to examine whether the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, could improve HbA1c (< or =7.4%) with minimal weight gain (< or =1 kg) compared with insulin glargine.
DOI Link: 10.1111/j.1463-1326.2009.01154.x
eISSN: 1463-1326
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.